• Blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed. (medworm.com)
  • Authors: Schultz L, Gardner R Abstract Immunotherapies have been successfully developed for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) with FDA approval of blinatumomab, inotuzumab, and tisagenlecleucel for relapsed or refractory patients. (medworm.com)
  • Authors: Mrowka P, Glodkowska-Mrowka E Abstract Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear receptor acting as a transcription factor involved in the regulation of energy metabolism, cell cycle, cell differentiation, and apoptosis. (medworm.com)
  • In the future, the discovered TCRs could be potentially transferred into patient recipient T cells for subsequent adoptive T-cell therapy to combat tumor cells expressing the selected neoantigens. (medigene.com)
  • Medigene's TCR technology for adoptive T-cell therapy is one of the company's three highly innovative and complementary immunotherapy platforms in immuno-oncology. (medigene.com)
  • In June, Kite Pharma and bluebird bio, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies. (wikipedia.org)
  • The TCR-T technology aims at arming the patient's own T cells with tumor-specific T cell receptors. (biospace.com)
  • There is increasingly a valid concern that anti-cancer immunity may be compromised in the elderly due to (i) their low amounts of naïve T cells (potentially leading to holes in the repertoire for neoantigens), (ii) "exhaustion" of potentially tumor-specific memory T cells, and (iii) higher amounts of suppressive cells. (springer.com)
  • Using Medigene's dendritic cell technologies, it was possible to induce neoantigen-specific T-cell responses in cultures in vitro , thereby identifying the best suited tumor-specific mutations for use in DC vaccines to raise potent immune responses in patients. (medigene.com)
  • First, given in combination with mAbs, Fcγ-CR T cells mediate anticancer activity in vitro and in vivo by an antibody-mediated cellular cytotoxicity mechanism. (frontiersin.org)
  • This immunotherapy approach attempts to overcome the patient's tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient's T cells outside the body (ex vivo). (biospace.com)
  • Furthermore, lenalidomide enhanced the antitumor activity and persistence of adoptively transferred CS1 CAR T cells in vivo . (aacrjournals.org)
  • however, uncertainties surround the optimal target as well as enhancing the persistence and expansion of engineered cells in vivo . (aacrjournals.org)
  • As part of this effort, BioNTech will utilize its mRNA formulation technology, which enables targeted mRNA delivery in vivo, to generate novel cancer immunotherapies. (marketwatch.com)
  • Following T-cell engineering, resulting cells are expanded ex vivo with interleukin 2 (IL-2) before administration. (bioprocessintl.com)
  • Under the partnership, the Swiss major will test its new PD-L1 (programmed death ligand-1) drug atezolizumab alongside California-based biotech Kite's immunotherapy CAR-T (chimeric antigen-receptor T-cell) treatment KTE-C19 in patients with refractory, aggressive non-Hodgkin lymphoma (NHL). (fiercebiotech.com)
  • We are excited by Kite's commitment to driving innovation in this field and look forward to working together to realize the full promise of cell therapy in treating cancer. (prnewswire.com)
  • In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite's most advanced immunotherapy product candidate - KTE-C19 CAR - can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma, known as diffuse large B cell lymphoma (DLBCL). (wikipedia.org)
  • MediGene AG (FSE: MDG1, Prime Standard, SDAX) today announced that it has entered into an exclusive license agreement with Leiden University Medical Center (LUMC), the Netherlands, for worldwide rights to develop, manufacture, and commercialize an HA-1-specific T cell receptor (TCR) as a targeted immunotherapy for cancer. (biospace.com)
  • Martinsried/Munich (pta/25.02.2019/07:30) Medigene AG (FSE: MDG1, Prime Standard, SDAX) reported today that the European Patent Office intends to grant a European Patent for the patent application EP3303591A1 covering a T cell receptor (TCR) building block library that is suitable for rapid reconstruction and testing of newly discovered TCR sequences against classical antigens as well as neoantigens. (biospace.com)
  • Prof. Dolores Schendel, CEO and CSO of Medigene AG (MDG1, Frankfurt, Prime Standard), will present a new approach to develop T-cell receptors (TCRs) against neoantigens at the Neoantigen Summit 2016 in Boston (USA) on 16 November. (medigene.com)
  • TCR-T therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR-T) therapy. (biospace.com)
  • The research of the Department of Hematology aims to translate basic research achievements into clinical applications in the field of hematopoietic stem cell transplantation and immune therapy of cancer. (biospace.com)
  • Subscribe to Cell Therapy Roadmap, our email newsletter that highlights timely cell therapy developments. (terumobct.com)
  • Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy. (terumobct.com)
  • Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma. (marketresearch.com)
  • Recently, chimeric antigen receptor-modified T- (CART-) cell-based therapy, an innovative approach to tumor treatment, was demonstrated to potentially exhibit MHC-independent antitumor effects. (hindawi.com)
  • It has already been given a breakthrough therapy status from the FDA for the treatment of patients with refractory diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. (fiercebiotech.com)
  • Finally, CS1 CAR T cells and lenalidomide were administered to treat multiple myeloma-bearing mice as combinatorial therapy. (aacrjournals.org)
  • The company's mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. (thermofisher.com)
  • In October 2017, Kite Pharma's therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. (wikipedia.org)
  • It has US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). (wikipedia.org)
  • Covering multiple cancer types, the deal is a sign of the pharma industry's confidence in using immunotherapies - medicines that trigger the body's immune system into fighting a disease - to treat cancer. (pmlive.com)
  • The race towards nov- EGFR Epidermal growth factor receptor el CAR T treatment options for cancer patients has begun, EU European Union but without careful design of the constructs and overall under- FDA Food and Drug Administration standing of the factors that impact the ultimate outcome in GE Gene editing each case, the road towards commercial success may be long GMP Good manufacturing practise and winding. (deepdyve.com)
  • Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo's technology, based on the achievement of certain research, development, regulatory and successful commercialization milestones. (prnewswire.com)
  • Recent advances in TCR sequencing of single T cells now also allow multiple TCRs that are potentially specific for neoantigens to be identified in patient tumors. (biospace.com)
  • Medigene has demonstrated the ability to utilize T cells from healthy donors together with a new automated system established in Medigene's laboratories to identify and characterize TCR candidates against neoantigens for individualized cancer patient treatment. (medigene.com)
  • Medigene's technologies yielded numerous T-cell clones and thereof identifiable TCRs against diverse neoantigens. (medigene.com)
  • With more than 2,000 members, SITC is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. (pharmiweb.com)
  • UCART123 is in phase 1 trials for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukaemia (AML). (wikipedia.org)
  • These 92 constructs serve as the basic building blocks of the newly patented TCR library of Medigene that also includes design elements for flexible exchange of any other TCR region and adaptor sequences that enable reconstructed TCRs to be shuttled into recipient T cells by different means. (biospace.com)
  • The podium presentation titled, " Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations, " was presented on November 10, and the poster presentation with the same title was available at various times throughout the conference. (pharmiweb.com)
  • Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG (1998) Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. (springer.com)
  • Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (stanford.edu)
  • SWOG) About 32% of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the US Food and Drug Administration to eventually pull the combination from the current study. (medworm.com)
  • Medigene is establishing a pipeline of recombinant T cell receptors and has a collaboration with bluebird bio, Inc. for the development of six TCR-Ts. (biospace.com)
  • This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs). (marketwatch.com)
  • The antibodies would effectively act as "police," identifying and attaching to "bad guy" targets in order to turn off or quiet down malignant cells. (techcrunch.com)
  • Yeah…I know…) For the WebMD warriors and the rest of us with a medical background that stopped at tenth-grade chemistry, CAR-T essentially looks to attack cancer cells by utilizing the body's own immune system. (techcrunch.com)
  • The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL. (wikipedia.org)
  • That's the story at Viela Bio, a Maryland-based company exploring treatments for inflammation and autoimmune diseases, which raised a $250 million Series A led by three Chinese firms. (techcrunch.com)
  • In proof-of-principle studies, Medigene was able to deliver findings for both major immunotherapy routes the Company follows. (medigene.com)
  • Immunotherapy has shown promise as an avenue to develop potentially curative treatments for people with cancer, and Sanofi has strategically launched a number of inter-company collaborations in this area in recent months, ' said Elias Zerhouni, President, Global R&D at Sanofi. (marketwatch.com)
  • The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer. (wikipedia.org)
  • Finally, we compare the advantages and limitations of the CD16-CR T cell technology with those of CAR T cell methodology. (frontiersin.org)
  • And although it has highlighted the tangible potential for an immunotherapy to reach approval, the attention garnered by these approaches also has underscored the need for significant improvements in bioprocessing technologies and capacities to meet potential and expected market requirements. (bioprocessintl.com)